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Abstract
Respiratory syncytial virus is a leading cause of lower respiratory tract illness among infants, the elderly and
immunocompromised individuals. Currently, there is no effective vaccine or disease modifying treatment available and
novel interventions are urgently required. Cathelicidins are cationic host defence peptides expressed in the inflamed lung,
with key roles in innate host defence against infection. We demonstrate that the human cathelicidin LL-37 has effective
antiviral activity against RSV in vitro, retained by a truncated central peptide fragment. LL-37 prevented virus-induced cell
death in epithelial cultures, significantly inhibited the production of new infectious particles and diminished the spread of
infection, with antiviral effects directed both against the viral particles and the epithelial cells. LL-37 may represent an
important targetable component of innate host defence against RSV infection. Prophylactic modulation of LL-37 expression
and/or use of synthetic analogues post-infection may represent future novel strategies against RSV infection.
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Introduction
Respiratory syncytial virus (RSV) is the major cause of viral
bronchiolitis in young children worldwide, and a leading cause
of morbidity and mortality in infants, elderly and immunocom-
promised individuals [1,2]. In addition to major morbidity (33.8
million episodes worldwide per year), RSV bronchiolitis also
leads to significant mortality in the developing world with up to
200,000 deaths annually in young children worldwide [1]. RSV
infection results in inflammatory lower respiratory tract disease
in about 30% of infants who become infected, and, in ,2% of
all infants, RSV bronchiolitis is potentially life-threatening and
requires admission to hospital (reviewed in [3]). Although most
infants in developed countries recover, these children have an
increased risk of recurrent wheeze and RSV infection has been
implicated in the later development of asthma [4]. Despite the
prevalence of RSV bronchiolitis, susceptibility remains poorly
understood, there is no vaccine available and, apart from
supportive measures, there is no specific effective treatment
(reviewed in [5]). A clearer understanding of the host defence
factors that contribute to effective protection against RSV in the
majority of those exposed to this virus should inform the
development of novel prophylactic and/or therapeutic strate-
gies.
Cationic host defence peptides (CHDP; also known as
antimicrobial peptides) are key components of innate defences
against infection, with both microbicidal and host defence
modulatory functions (reviewed in [6]). In addition to their well
described bactericidal potential, CHDP have more recently
been shown to have antiviral properties (reviewed in [7]).
Cathelicidins are multifunctional immunomodulatory CHDP
expressed in a broad range of tissues in infection and
inflammation (reviewed in [8,9]). The sole human cathelicidin,
Human Cationic Antimicrobial Peptide of 18KDa (hCAP-18),
from which the active form LL-37 is generated proteolytically
[10], is expressed primarily by neutrophils and epithelial cells.
Airway epithelial cell expression of LL-37/hCAP18 is induced in
vitro by RSV infection [11], and is significantly enhanced by the
1,25OH metabolite of vitamin D [12]. In addition, a recent
study of children with RSV bronchiolitis demonstrated that
median serum levels of hCAP-18 were significantly lower in
children with RSV bronchiolitis than in those with human
rhinovirus induced bronchiolitis [13]. Furthermore, RSV-
infected children whose hCAP-18 levels were lower than the
median were found to be more likely to be hospitalised for
prolonged periods than those with hCAP-18 levels above the
median. These findings suggest an antiviral role for human
cathelicidin in host defence against RSV.
In order to determine the antiviral potential of LL-37 against
RSV, we examined the impact of LL-37 on RSV infection in vitro,
establishing the effect of this CHDP on viral particles and its
protective impact upon human epithelial cells.
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Materials and Methods
Peptide synthesis
LL-37, TAMRA-labelled LL-37, scrambled LL-37 and trun-
cated LL-37 partial peptides (all sequences in Figure 1a) were
either purchased from Activotec (Cambridge, UK) or synthesised
as described below. Peptide purity was .95% by RP-HPLC and
net peptide content determined by amino acid analysis. NovaSYN
TGT resin preloaded with Fmoc-Ser(tBu)-OH (0.05 mM) was
transferred to an automated peptide synthesiser (ABI 433A)
reaction vessel for peptide chain elongation employing 10
equivalents of each standard Fmoc-protected amino acid employ-
ing the FastmocTM protocol. Following chain elongation the fully
protected resin-bound peptide was treated with trifluoroacetic
acid: ethanedithiol: water (95: 2.5:2.5, 4.0 ml) for 5 hours. The
resin was filtered off and the filtrate was added to cold diethyl ether
(40 ml), which induced precipitation. The precipitate was collected
by centrifugation at 3000 rpm, 4uC for 15 min. The ether layer
was then decanted and the precipitated peptide was washed once
more with cold diethyl ether (40 ml). The white precipitate was
then dissolved in water and purified by semi-preparative reverse
phase (RP)-HPLC (gradient: 5–60% acetonitrile/45 min). Frac-
tions containing product were identified by LC-MS, pooled and
lyophilised. Lyophilised peptides were reconstituted in endotoxin
free water at 5 mg/ml stock concentration and determined to be
endotoxin-free using a Limulus Amebocyte Lysate Chromogenic
Endotoxin Quantitation Kit (Thermo Scientific, UK). Peptide
functionality was confirmed by assessing anti-endotoxic activity
[14].
Cell culture
HEp-2 cells (ATCC CCL-23), Vero cells (ATCC CCL-81) and
16HBE14o- transformed human bronchial epithelial cells (a kind
gift from Dieter Gruenert, University of California [15]) were
cultured in DMEM/F12 (Gibco/Life Technologies Ltd, Paisley,
UK) or RPMI (Gibco) respectively, supplemented with 2 mM L-
glutamine (PAA Laboratories, Yeovil, UK) and 10% FCS (Biosera,
East Sussex, UK), at 37uC and 5% CO2. 16HBE14o
- cells were
cultured on wells previously coated with a basement layer of
collagen IV (5 mg/ml), fibronectin (10 mg/ml) and bovine serum
albumin (100 mg/ml) (all Sigma Aldrich, Dorset, UK).
Virus propagation
RSV strain A2 (VR-1540) was purchased from ATCC. RSV
was propagated in HEp-2 cells by infecting 56106 cells that were
allowed to grow on confluent overnight in serum-free VP-SFM
media (Gibco) for 2 hours with 0.1 plaque forming units (PFU)
followed by removal of inoculum. Cells were then incubated for
24 hours in 10% FCS Gold (PAA Laboratories) supplemented VP-
SFM. Cells were then incubated for a further 5 days in 2% FCS
Gold supplemented VP-SFM, cells were harvested and superna-
tant was snap-frozen and stored at 280uC.
Immunoplaque assay
An immunoplaque assay (based on [16]) was used to quantify
RSV infected cells. Optimisation of the infection protocol was
conducted using serial dilutions of RSV to assess the PFU of
propagated virus stocks and establish an optimal MOI of 0.005
that allowed reliable counting of individual infected cells
(approximately 100–250 per well) in a control infected culture at
24 hours. Peptide treatments were therefore primarily evaluated at
RSV MOI= 0.005, however higher MOIs (up to 1) were also
tested and similar effects of peptides were observed (data not
shown). For experimental assessment of the antiviral effects of
peptides, cells were seeded at 26104 per well in 96- well plates and
cultured overnight, then washed and infected, in fresh serum-free
medium. After 2 hours, inoculum was removed and cells were
cultured in fresh medium for 24, 48 or 72 hours before analysis.
Peptides were added before, after or concomitantly with RSV
infection as described for individual experiments. Monolayers
were fixed in absolute methanol/2% hydrogen peroxide solution
for 30 minutes and washed twice with PBS. Cells were exposed to
monoclonal biotinylated anti-RSV antibody in 5% BSA/PBS for
1 hour (1:200, AbD Serotec, Kidlington, UK), washed twice with
PBS and were incubated with extravidin peroxidase in 5% BSA/
PBS for 30 minutes (1:500, Sigma Aldrich). Cells were stained
using 3-amino-ethylcarbazole substrate (Invitrogen/Life technolo-
gies) according to manufacturer’s instructions for 15 minutes,
washed 3 times with PBS and infected RSV positive foci were
quantified by light microscopy, counting 3–4 wells per condition.
For later timepoint analysis (48 and 72 hours post infection with
RSV MOI= 0.0005), fixed and stained monolayers were exam-
ined by light microscopy and images were captured using an
EVOS fl imaging system (PEQLAB Ltd, UK). Quantification was
performed using the ImageJ plugin Treshold_colour to measure
the percentage of cells positive for RSV infection. 3 wells were
assessed per condition, using 4 random fields of view captured per
well. To assess the production of infectious viral particles,
supernatants were serially diluted and transferred to fresh HEp-2
monolayers, incubated for 2 hours at 37uC, washed, incubated for
a further 24 hours and then assessed by immunoplaque assay.
Direct viral inactivation assay
A modified viral inactivation assay [17] was performed. 1 ml
RSV (PFU=26103, equivalent to MOI= 0.05) was mixed with
25 mg/ml LL-37, followed by immediate 10-fold dilution in serum-
free medium to reach sub-therapeutic concentrations of LL-37
(2.5 mg/ml) and RSV MOI= 0.005. 25 mg/ml scrambled LL-37
or PBS were used as negative controls. HEp-2 monolayers were
infected with this virus/peptide mixture for 2 hours then washed,
before cells were cultured in serum-free medium for 24 hours.
Fixed monolayers were subjected to immunoplaque assay.
Visualisation of TAMRA-labelled LL-37
HEp-2 cells were treated with unlabelled- or red-fluorescent
tetramethylrhodamine (TAMRA)-labelled LL-37 at 25 mg/ml for
1 hour, followed by a PBS wash. Hoechst stain was added at 1 mg/
ml for 30 minutes to visualise nuclei, and live cells were assessed by
confocal microscopy, using a Leica SP5 confocal microscope with
a 636 objective and Leica Application Suite Advanced Fluores-
cence software. A minimum of 4 fields of view were assessed for
each condition.
Western blotting
HEp-2 cells were treated with LL-37 for 1 hour, or left
untreated, followed by PBS washes or left unwashed. Cells were
lysed on ice using lysis buffer (20 mM Hepes, 0.3 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM Orthova-
nadate, 0.5% TritonX100) with Complete Protease Inhibitor
Cocktail tablets (Roche Applied Science, UK; 1 tablet dissolved in
1 ml ddH2O and used at a 1 in 50 dilution). A BCA test was used
to determine protein concentration, as per manufacturer’s
instructions (Thermo Scientific, UK) and equal amounts of
protein were incubated (5 min, 95uC) with sample buffer and
reducing agent (Invitrogen). SDS polyacrylamide gel electropho-
resis was performed, using 16% denaturing gels (100 V, 5 min,
then 120 V, 85 min), before proteins were transferred to PVDF
membranes by electro-blotting (100 V, 90 min). Membranes were
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blocked with 5% milk in PBS for 1 hour and incubated with LL-
37 primary antibody (Innovagen AB, Lund, Sweden; 1:1000, 5%
milk/PBS) overnight. Following 3 washes in Tris buffered saline
with 0.05% Tween 20 (TBST), membranes were exposed to
extravidin-peroxidase coupled secondary antibody (mouse anti-
rabbit, Jackson ImmunoResearch, Suffolk, UK; 1:10,000) for
1 hour, then washed with TBST. Chemiluminescence substrate
(GE Healthcare Life Sciences, Buckinghamshire, UK) was added
to membranes for 1 minute and the resulting chemiluminescence
was detected by exposition to film.
Assessment of cytopathic effects
HEp-2 cells were treated with LL-37, a scrambled control LL-
37 at 50 mg/ml or ribavirin (200 mM; Sigma Aldrich), in the
presence or absence of simultaneous infection with RSV
(MOI= 0.005). Cells were incubated for 2 hours at 37uC, washed
and placed in fresh media. In some wells LL-37 or ribavirin was
added again at this point (for ‘‘continuous treatment’’). Cells were
cultured at 37uC for 24 hours or 5 days, after which the number of
viable metabolically active cells was assessed using an MTT assay
(Sigma Aldrich) according to manufacturer’s instructions (7.5 mg/
ml, 37uC, 4 hours). Resulting formazan was dissolved in
dimethylsulfoxide (Sigma Aldrich) and optical density was
measured at 450 nm. Alternatively, cells simultaneously treated
with or without LL-37 in presence or absence of RSV infection
were allowed to dry for 10 minutes before they were fixed and
permeabilised using ice-cold acetone/methanol (1:1) for 10
minutes at 4uC. After a wash with PBS, cells were subjected to
TUNEL assay using an In situ cell death kit (Roche Applied
Science, UK) according to manufacturer’s instructions. Cells were
washed three times with PBS and 1 mg/ml DAPI was included in
the second wash (3 minutes staining). Cells were examined by
fluorescent microscopy, four representative images per well were
captured using an EVOS fl imaging system (PEQLAB Ltd) and
TUNEL positive and negative cells were quantified using ImageJ
(http://rsbweb.nih.gov/ij/index.html).
Statistical analysis
Statistical analyses were performed as described using Graph-
pad Prism version 5 for Windows (GraphPad Software, Inc., La
Jolla, CA, USA). For statistical analysis, immunoplaque counts
were log transformed. Statistical significance was assessed either
Figure 1. LL-37 has antiviral activity against RSV. a) Sequences of
LL-37, three 22-mer peptides (representing the N-terminal, central core
and C-terminal regions) and scrambled LL-37 peptide, b) HEp-2 or c)
16HBE14o- cells were infected with RSV (MOI = 0.005) and simulta-
neously treated with LL-37 or a scrambled control LL-37 (scrLL-37) at
the concentrations indicated for 2 hours. Cells were washed and
incubated for 24 hours at 37uC, and then the number of infected cells
was quantified. d) HEp-2 cells were exposed to LL-37 and RSV
(MOI = 0.005) simultaneously (‘‘Simultaneous’’ condition), for 2 hours,
or exposed for 2 hours to RSV that had been preincubated with LL-37
for 1 hour (‘‘37uC pre-incubation’’ and ‘‘4uC pre-incubation’’ conditions),
or exposed to RSV for 2 hours and washed before a 1 hour incubation
with LL-37 (‘‘Virus first’’ condition), or treated with LL-37 for 1 hour and
washed before a 2 hour infection with RSV (‘‘LL-37 first’’ condition).
Every treatment was followed by a wash step. After 24 hours at 37uC,
the number of infected cells was quantified. b, c & d) Infected cells were
quantified using an immunoplaque assay and expressed as a
percentage relative to untreated, RSV infected cells. Results are shown
as mean +/2 SEM of n = 3-5. For statistical analysis, RSV-positive foci
counts were log transformed and analysed by one way ANOVA with
Dunnett Multiple Comparison Post-tests to compare treatments to
untreated infected controls * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0073659.g001
LL-37 Possesses Anti-RSV Activity
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using a one-way analysis of variance (ANOVA) with Dunnett
Multiple Comparison post test, or a two-way ANOVA with
Bonferroni’s post test where appropriate. p#0.05 was considered
significant.
Results
LL-37 has antiviral activity against RSV
In order to assess the antiviral potential of LL-37 against RSV,
HEp-2 human epithelial cells were infected with RSV and
concomitantly treated with a concentration range of LL-37
peptide, then assessed by counting the number of RSV- infected
cells by immunoplaque assay after 24 hours. This simultaneous
exposure to virus and LL-37 resulted in a significant, concentra-
tion-dependent reduction in infectivity at $10 mg/ml of LL-37
(p,0.05), compared to virus alone (Figure 1b). The same effect
was observed when the human bronchial airway epithelial cell line
16HBE14o- was used (Figure 1c), demonstrating that the effect was
not specific to the HEp-2 cell line. A scrambled LL-37 control
peptide had no antiviral effect (Figure 1c), demonstrating that this
was not a non-specific effect of a cationic peptide. In order to
determine whether maximal antiviral effect required interaction
between the peptide and virus in advance of infection, the
sequence of peptide and virus addition to cell was then modified.
As a mimic of the physiological encounter between RSV and LL-
37 that might be expected to occur in the airway surface liquid in
vivo before reaching epithelial cells, virus was pre-incubated with
LL-37 (at 37uC or at 4uC, given the temperature sensitive nature
of RSV[18]), before HEp-2 cell infection. These conditions, in
which peptide may have effects on the cells, the virus or both, also
resulted in significant antiviral activity (Figure 1d; LL-37 effect
p,0.05 by one-way ANOVA), resulting in approximately 1 log
fewer infected cells at 25 mg/ml of LL-37 (p,0.01 at 37uC and
p,0.001 at 4uC), but not substantially different to the simulta-
neous addition of peptide and virus without preincubation. In
contrast, in these experiments, delaying LL-37 treatment until
2 hours after viral infection resulted in a loss of the antiviral effect
(Figure 1d), indicating that LL-37 treatment after infection does
not ‘‘rescue’’ infected cells. However, pre-incubation of HEp-2
cells with LL-37, followed by cell washing prior to infection, also
resulted in significantly less RSV infection (p,0.001; Figure 1d).
These data demonstrate that LL-37 has significant antiviral
activity against RSV infection of epithelial cells in vitro and suggest
that this peptide may exert its effects by directly affecting the viral
particle and/or by acting on epithelial cells to reduce their
susceptibility to infection.
The antiviral effects of LL-37 are protective against cell
death
We have previously demonstrated that LL-37 can induce
apoptosis in Pseudomonas aeruginosa-infected epithelial cells [19]. In
order to determine whether similar mechanisms could lead to
reduced infection through epithelial cell death, or whether LL-37
was actively protecting cells from infection, we examined the
number of viable, metabolically active HEp-2 cells by MTT assay
and induction of cell death by TUNEL assay. The treatment of
RSV-infected cells with LL-37 (#50 mg/ml) did not have any
substantial effect on the number of metabolically active HEp-2
cells at 24 hours (Figure 2a), nor any substantial effects on the low
background levels of apoptosis in this cell line (0.5–1.5% of HEp-2
cells were found to be TUNEL positive in the presence or absence
of RSV or LL-37 at 24 hours after infection; data not shown). In
order to determine longer term effects, treated cells were examined
for up to 5 days. The treatment of uninfected cells with LL-37
Figure 2. LL-37 is protective against RSV-induced cell death.
HEp-2 cells were treated with LL-37 at 0–50 mg/ml, a scrambled control
LL-37 at 50 mg/ml (Scr 50), or ribavirin (200 mM), in the presence (a & c)
or absence (b) of simultaneous infection with RSV (MOI = 0.005). Cells
were incubated for 2 hours at 37uC, washed and placed in fresh
medium. In some wells LL-37 or ribavirin was added again at this point
(c; ‘‘continuous treatment’’). Cells were cultured at 37uC for 24 hours (a)
or 5 days (b & c), after which the number of viable metabolically active
LL-37 Possesses Anti-RSV Activity
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(#50 mg/ml) did not affect the number of metabolically active
HEp-2 cells, even after 5 days (Figure 2b). In contrast LL-37 was
found to be protective in RSV infected cells (Figure 2c). HEp-2
cells were simultaneously incubated with RSV and LL-37 or
RSV and the antiviral agent ribavirin (as a positive control) for
two hours, before being washed and incubated for five days in
the absence of LL-37/ribavirin (Figure 2c; ‘‘pre-treatment’’
condition). Notably, LL-37 treatment resulted in significantly
more viable HEp-2 cells surviving RSV infection in a dose-
dependent manner (overall LL-37 effect p,0.001 by 1-way
ANOVA). Neither scrambled LL-37 nor the antiviral ribavirin
had any direct effect under these conditions. Since ribavirin
prevents viral replication, rather than cell infection, the effect of
continuous presence of treatment in the media over the five day
study was evaluated (Figure 2c; ‘‘continuous treatment’’
condition). Continuous treatment of RSV-infected HEp-2 cells
with either ribavirin or LL-37 resulted in a significant protection
of epithelial cells from cell death compared to the untreated
infected cells (LL-37 p,0.01 and ribavirin p,0.001), with
substantially greater protective effects than observed in the pre-
treatment condition (significantly different for ribavirin;
p,0.01, but not reaching statistical significance for LL-37).
These data demonstrate that LL-37 can protect against RSV-
induced cytopathic effects.
LL-37 directly affects RSV viral particles
In order to determine whether LL-37 could have a direct effect
upon RSV viral particles, a concentrated viral stock was exposed
to LL-37 at 25 mg/ml, immediately followed by a 1 in 10 dilution,
reducing the concentration of LL-37 to which cells were exposed
to below the effective antiviral level (to 2.5 mg/ml) before
incubation with HEp-2 cells. This was compared to pre-mixing
of virus (at standard concentration) with LL-37 at 2.5 mg/ml
before infection of HEp-2 cells (Figure 3a). The combination of
virus exposure to 25 mg/ml LL-37, with cell exposure to 2.5 mg/
ml LL-37, had significant antiviral effects (p,0.001), whereas the
combination of virus and cell exposure to 2.5 mg/ml LL-37 had no
significant effects and was significantly different from the former
(p,0.01). No effect was observed using scrambled LL-37 under
the same dilution conditions. These data demonstrate that the
antiviral properties of LL-37 against RSV are at least partly due to
a direct interaction with the viral particles, an effect that was
separable, under these conditions, from any peptide-mediated
effects on the cells.
LL-37 modulates epithelial cell susceptibility to RSV
infection
Having demonstrated that pre-treatment of epithelial cells with
LL-37 could protect against subsequent infection by RSV (Fig. 1c),
the longevity of that protective effect was determined by delaying
RSV infection of cells for a variable period of time after LL-37
treatment and washing of cells (Figure 3b). A significant protection
against RSV infection was observed for up to 3 hours after LL-37
treatment and cell washing (p,0.001). However, a time dependent
loss of protection was observed, with no protection evident
24 hours after LL-37 treatment and cell washing.
The pre-treatment of cells with LL-37, followed by washing of
the cells, was conducted in an effort to remove LL-37 from the cell
culture system before addition of RSV. However, we have
previously demonstrated that LL-37 can interact with epithelial
cells was assessed using an MTT assay with measurement of optical
density at 450 nm, expressed as a percentage of untreated infected (a &
c) or untreated (b) cells. Results are shown as mean +/2 SEM of n = 3-4.
The data were analysed by 1-way ANOVAs with Dunnett Multiple
Comparison Post-tests comparing peptide concentrations against the
‘‘no peptide’’ control (** p,0.01, *** p,0.001), and 2-way ANOVA with
Bonferroni Post-tests comparing pre-treatment protocols versus con-
tinuous treatments (## p,0.01).
doi:10.1371/journal.pone.0073659.g002
Figure 3. LL-37 has protective antiviral effects by acting both
on viral particles and cells. a) RSV (MOI = 0.05) was pre-mixed with
LL-37, or a scrambled LL-37 control peptide (scrLL-37) at 25 mg/ml,
followed immediately by a 1:10 dilution that was used to infect HEp-2
cells for 2 hours or RSV (MOI = 0.005) was pre-mixed with LL-37 at
2.5 mg/ml before immediate use. b) HEp-2 cells were simultaneously
treated for 2 hours with RSV (MOI = 0.005) and LL-37 (‘‘sim LL-37’’
condition), or a scrambled LL-37 control peptide (‘‘sim scrLL-37’’
condition), at 25 mg/ml, or were pre-treated with 25 mg/ml LL-37 for
1 hour, washed and then infected with RSV (MOI = 0.005, 2 hours) at 1,
3 or 24 hours after initial exposure to LL-37. Cells were washed and
cultured for 24 hours at 37uC, then the number of infected cells was
quantified using an immunoplaque assay and expressed as a
percentage relative to untreated, RSV infected cells. Results are shown
as mean +/2 SEM of n$3. For statistical analysis, RSV-positive foci
counts were log transformed and analysed by a) two-way ANOVA with
Bonferroni post-test to compare LL-37 treatment with appropriate
control and the effects of dilution, or b) one way ANOVA with Dunnett
Multiple Comparison Post-tests to compare treatments to untreated
infected controls; ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0073659.g003
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cells and be actively transported into the cell [20]. Thus, whole cell
lysates were examined by western immunoblot for LL-37 before
and after cell washing (Figure 4a). No expression of hCAP18
(18 kDa) was observed in untreated cells or treated cells. No
difference in the levels of exogenous LL-37 were observed between
washed and unwashed peptide treated cells, indicating that
washing did not remove the peptide from the HEp-2 cells. In
order to confirm retention of the peptide by HEp-2 cells, cells were
exposed to a TAMRA-labelled LL-37, washed and then imaged
by fluorescent confocal microscopy (Figure 4b). TAMRA-labelled
LL-37 was clearly observed to be associated with the epithelial
cells, but not with the tissue culture plastic. Confocal z-stack
analysis indicated that this peptide was predominantly intracellular
(data not shown) with perinuclear distribution (Figure 4b).
The activity of the internalised peptide is unclear, but an
intracellular receptor (GAPDH) for LL-37 has been proposed [21],
and the antiviral effect of LL-37 pre-treatment of cells raised the
possibility that LL-37 might induce a protective antiviral state in
treated epithelial cells. As LL-37 has been shown to modulate
expression of antiviral type I interferons in other systems [22]
experiments were repeated in the type I interferon deficient [23]
Vero cell line (Figure 4c). LL-37 demonstrated identical significant
antiviral activity (p,0.001) against RSV in both cell lines,
indicating that modulation of type I interferons was not required
for the protective effect of LL-37. These data demonstrate that
cell-associated LL-37 can mediate protection from RSV infection,
likely independently of the direct activity on viral particles, but the
mechanism by which this cell-associated peptide protects the
epithelial cells remains to be determined.
LL-37 can protect epithelial cells against spread of virus
infection
In order to examine the effects of LL-37 on the production of
new infectious viral particles, HEp-2 cells were infected with RSV
in the presence or absence of LL-37 for 2 hours, then cultured in
fresh media for up to 3 days, with or without the continued
presence of LL-37 or scrambled LL-37. At selected timepoints,
infectivity of the supernatant from these cells was assessed for its
ability to infect fresh HEp-2 cell cultures (Figure 5a). Treatment
with LL-37 (but not scrambled LL-37) resulted in the production
of significantly (p,0.001), and very substantially, fewer new
infectious viral particles, even reducing infectivity up to day 3
(statistically significantly when LL-37 remained in the media;
p,0.05).
In the previous experiment (Figure 1d), addition of LL-37 at
2 hours after RSV infection had no effect on the number of
infected cells at 24 hours. However, the effect on production of
new infectious viral particles suggested that LL-37 might prevent
the spread of infection from initially infected cells to uninfected
cells in the culture over a longer time course. In order to examine
this in vitro, HEp-2 cells were infected with a lower inoculum and
evaluated by immunoplaque assays over 3 days (Figure 5b). The
number of infected cells dramatically increased by day 2 in
untreated cultures (Figure 5b, panel 1) and those exposed to
scrambled LL-37 (Figure 5b, panel 4), rapidly reached uncount-
able levels of infected cells with death and substantial loss of cells
by day 3 (Figure 5b, panels 5 & 8). In contrast, this spread of
infection beyond the cells initially infected was minimised when
LL-37 had been added simultaneously with RSV (Figure 5b,
panels 2 & 6), or indeed even after RSV infection had been
established (Figure 5b, panels 3 & 7). A quantitative image analysis
approach to these data significantly underestimates the number of
infected cells where cell death and loss has occurred, but
nevertheless demonstrates significant protection against spread of
Figure 4. LL-37 is retained by epithelial cells and does not act
via modulation of type I interferon production. HEp-2 cells were
treated with 25 mg/ml of LL-37 (a) or TAMRA-labelled LL-37 (b) for
1 hour, or left untreated. a) LL-37 treated cells were then subjected to
repeated wash steps or left unwashed, before cell lysis and protein
collection. The presence of LL-37 was assessed by western immunoblot.
Data is representative of n= 3 independent experiments. b) TAMRA-
labelled LL-37 treated cells were washed and then Hoechst staining was
added before imaging by confocal microscopy. A merged brightfield/
Hoechst/TAMRA-LL-37 image is shown, nuclei in blue and TAMRA-
labelled LL-37 in red. Image is at 636magnification. c) Vero cells and
HEp-2 cells were infected with RSV (MOI = 0.005) and simultaneously
treated with LL-37 or a scrambled control LL-37 (scrLL-37) at 25 mg/ml
for 2 hours. Cells were washed, incubated for 24 hours at 37uC, then the
number of infected cells was quantified using an immunoplaque assay
and expressed as a percentage relative to untreated, RSV infected cells.
Results are shown as mean +/2 SEM of n = 3-5. For statistical analysis,
RSV-positive foci counts were log transformed and analysed by one way
ANOVA with Dunnett Multiple Comparison Post-tests to compare
treatments to untreated infected controls *** p,0.001.
doi:10.1371/journal.pone.0073659.g004
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infection from initially infected cells over 2 to 3 days, regardless of
whether LL-37 was added concomitantly with, or after viral
infection (Figures 5c & d). These data demonstrate that LL-37 can
significantly inhibit the spread of newly produced infectious
particles.
The antiviral activity of LL-37 is retained by a truncated
peptide fragment
Having established the anti-RSV activity of LL-37, partial LL-
37 peptides were utilised to determine the antiviral properties of
truncated forms. Three 22-mer peptides [24] were used, which
correspond to the N-terminal (amino acids 1–22), central core
(amino acids 12–33) and C-terminal (amino acids 16–37) sequence
of the LL-37 peptide (Figure 1a). Simultaneous treatment of HEp-
2 cells with RSV and peptides from this panel revealed significant
antiviral activity for full length LL-37 and the central core
fragment, but no effects for the N-terminal and C-terminal
fragments (Figure 6). These data demonstrate that shorter peptide
analogues, more amenable to the development of novel therapeu-
tics, retain antiviral activity.
Discussion
RSV is a major cause of morbidity and mortality globally,
particularly in infants, for which there is currently no effective
vaccination or treatment available. In experimentally induced
RSV infection in adult volunteers, early high viral titres have been
found to correlate with severity of inflammatory disease manifes-
tations [25]. In addition, more severe disease in infants is
associated with high viral titres in early stages of naturally-
occurring RSV bronchiolitis [26]. Thus, components of innate
host defence with the capacity to reduce viral load would be
expected to prevent or reduce severe disease. Here, we demon-
strate for the first time that the cationic host defence peptide LL-37
has effective antiviral activity against RSV in vitro, implicating this
Figure 5. LL-37 inhibits the production of new viral particles
and the spread of infection. a) HEp-2 cells were simultaneously
exposed to RSV with either 25 mg/ml LL-37 or scrambled LL-37 (scrLL-
37) for 2 hours, washed and incubated in fresh media with
(‘‘continuous’’), or without (‘‘sim’’) replacement of LL-37 or scrambled
LL-37 at 25 mg/ml, at 37uC for 1 day or 3 days. Supernatants were then
transferred in serial dilution to infect fresh HEp-2 cells and incubated for
2 hours, before these cells were incubated for 24 hours and assessed by
immunoplaque assay, expressed as a percentage relative to those
infected with supernatant from untreated, RSV infected cells. Results are
shown as mean +/2 SEM of n = 3. For statistical analysis, RSV-positive
foci counts were log transformed and analysed by one way ANOVA with
Dunnett Multiple Comparison Post-tests to compare treatments to
untreated infected controls * p,0.05, *** p,0.001, b, c & d) HEp-2 cells
were either infected with RSV alone (MOI = 0.0005) for 2 hours (b,
panels 1 & 5), simultaneously exposed to RSV with either 25 mg/ml LL-
37 (b, panels 2 & 6; c & d, ‘‘LL-37 sim’’) or scrambled LL-37 (b, panels 4 &
8; c & d, ‘‘scrLL-37 sim’’) for 2 hours, or incubated with RSV alone for
2 hours, then washed, before 25 mg/ml LL-37 was added for 1 hour (b,
panels 3 & 7; c & d, ‘‘LL-37 virus first’’). Subsequently, cells were washed
and cultured in fresh media for 48 hours (b, panels 1–4; c) or 72 hours
(b, panels 5–8; d) at 37uC, before immunoplaque assay. Extent of
infection in different treatments was evaluated by light microscopy
with infected cells staining dark (b). Images are representative of n = 3
independent experiments. Magnification640. c & d) Areas of infection
on light micrographs were quantified from 4 random fields per sample
from each of n= 3 independent experiments using Image J. Data
represent +/2 SEM of n = 3. Analysis was performed by one way ANOVA
with Dunnett Multiple Comparison Post-tests to compare treatments to
untreated infected controls ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0073659.g005
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peptide as a targetable host defence factor with a potentially key
role in susceptibility to RSV infection in vivo.
LL-37 is a pleiotropic CHDP, cleaved from the sole human
cathelicidin hCAP-18. This peptide can be detected in a broad
range of tissues and bodily fluids including plasma, bone marrow,
airway surface fluid, skin, sweat, reproductive tract, semen, urine,
breast milk and vernix (reviewed in [27]). Produced primarily by
neutrophils and epithelial cells, hCAP-18/LL-37 is upregulated in
response to infection, inflammation and wounding, and detected
at higher concentrations in the bronchoalveolar lavage fluid of
individuals in the context of lung infections, reaching average
levels of approximately 20–25 mg/ml [28,29]. More specifically,
the expression of CAMP (the gene encoding hCAP-18) can be
regulated by the active vitamin D metabolite 1,25-dihydroxyvita-
min D3 (1,25OH Vit D3), acting via a vitamin D response element
in the CAMP gene promoter [12,30,31], an effect that can promote
RSV-induced hCAP-18 production [11]. In addition to well
described bactericidal properties, we, and others, have recently
demonstrated that LL-37 has antiviral activity against a number of
viruses (reviewed in [7]), including influenza in vitro [32,33] and in
vivo [32]. Although the specific mechanisms involved remain
largely undetermined.
We now demonstrate that LL-37 has concentration-dependent
antiviral activity against RSV in vitro, capable of decreasing the
number of initially infected cells by approximately 1 log at the
physiologically relevant [28,29] concentration of 25 mg/ml. LL-37
prevented virus-induced cell death in epithelial cultures, signifi-
cantly inhibited the production of new infectious particles and
diminished the spread of infection. The effect was maximal when
peptides were premixed with virus, or added simultaneously.
However, significant depression of the extent of viral infection
after three days was seen (Figure 5) even when the peptide was not
added until two hours after infection of the cells, despite no effect
on the number of entry events being observed at 24 hours under
these conditions (Figure 1c). The specific events in the infection
cycle that are affected by LL-37 remain to be determined.
Nevertheless, these data suggest that higher baseline endogenous
levels of LL-37 and/or enhanced production of LL-37 in response
to RSV infection would offer protection in the lung. This
hypothesis was validated by the recent study demonstrating
clinical associations between low serum cathelicidin levels in
children and both the likelihood of RSV bronchiolitis and the
severity of disease [13]. These studies raise the possibility that
interventions capable of enhancing upregulation of LL-37 levels in
vivo could be used in RSV infection, given prophylactically in high
risk individuals, such as infants predisposed to repeated RSV
bronchiolitis.
The development of strategies to induce LL-37 expression is
currently focused on the use of drugs such as butyrate and/or the
use of vitamin D supplementation (reviewed in [34]). Butyrate is a
short-chain fatty acid produced by bacterial fermentation of
dietary fibre in the colon. 4-phenylbutyrate (PBA), an analogue of
butyrate that is already licenced for use in humans, can effectively
upregulate hCAP-18/LL-37 expression in vitro, including in airway
epithelial cells [35], and in vivo in a model of Shigella infection [36]
and has potential where more acute, short term upregulation is
required. Low serum 25(OH) VitD3 levels, and the decrease in
levels observed during winter [37], are associated with the risk of
respiratory infections, with a 7% reduction in adult respiratory
infection reported for every 10 nM/l increase in serum 25(OH)
VitD3 reported [38]. In addition, newborns with low cord blood
25(OH) VitD3 levels were found to have a significantly greater risk
of developing RSV-associated lower respiratory tract infections
[39]. Expression of hCAP-18/LL-37 can be regulated by vitamin
D [12,30,31] and further upregulated by exposure to RSV in the
presence of vitamin D [11]. An association between serum 25(OH)
VitD3 and hCAP-18/LL-37 expression has not yet been definitely
demonstrated in vivo. Nevertheless, these studies raise the
possibility that vitamin D supplementation (particularly in winter
in the northern hemisphere), should be considered as a novel
preventative strategy against RSV infection. Furthermore, LL-37
expression may represent a candidate mechanism involved in
understanding these observations.
In addition to prophylactic modulation of LL-37 expression, our
data raise the possibility that LL-37 peptide administration may
also have potential in post-exposure prophylaxis, given in the early
stages after infection to minimise the spread of RSV in the
epithelium, viral load and thus the severity of disease. In vivo
modelling is required to evaluate the efficacy of such an approach,
but the observation that antiviral activity is retained by a truncated
peptide demonstrates the potential to develop shorter synthetic
analogues for future testing. Interestingly, our evaluation of these
previously characterised [24] partial peptides representing the N-
terminus (amino acids 1–22), a central portion (amino acids 12–33)
and the C-terminus (amino acids 16–37) of LL-37 suggests that the
antiviral activity may relate to the same core peptide region
previously identified for antibacterial activity [24,40] and for the
capacity to induce secondary necrosis of apoptotic cells [41].
The specific mechanisms by which LL-37 has antiviral activity
against RSV are now under evaluation, but remain to be
determined. Our data demonstrate that LL-37 is capable of
having a direct effect on the viral particles. This was recently
demonstrated to occur in LL-37 treatment of influenza virus [33].
However, damage to the influenza viral membrane did not alter
the binding or initial uptake of virus by cells, but was proposed to
affect viral propagation or survival downstream of this. Interest-
ingly, similar to our observations with RSV, LL-37 was also found
to have antiviral activities against influenza when cells where
exposed to peptide in advance of infection [33]. However, in
contrast, LL-37-dependent inhibition of HIV-1 infectivity is
Figure 6. The antiviral activity of LL-37 is retained by a central
truncated fragment. HEp-2 cells were simultaneously treated with
RSV (MOI = 0.005) and full length LL-37 or one of three 22-mer peptide
fragments (all at 1 mg/ml, 10 mg/ml, and 25 mg/ml; see Figure 1a) for
2 hours before washing and 24 hours culture at 37uC. The number of
infected cells was quantified using an immunoplaque assay and
expressed as a percentage relative to untreated, infected cells. Results
are shown as mean +/2 SEM of n = 3. For statistical analysis, RSV-
positive foci counts were log transformed and compared to no peptide
treatment, analysed by 2-way ANOVA with Bonferroni Post-tests for
specific peptide concentrations ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0073659.g006
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mediated by inhibition of HIV-1 reverse transcriptase and
protease and does not require direct peptide-virus interaction
[42,43]. Furthermore, LL-37-mediated antiviral activity against
the non-enveloped adenovirus has also been reported [44],
suggesting important activities other than direct damage to viral
envelopes.
Our data demonstrate that LL-37 treatment in advance of viral
infection results in peptide retention and internalisation by the
epithelial cells, providing significant protection for at least 3 hours
after cell washing. This is in keeping with our previous
observations of active cellular uptake of LL-37 [20], and suggests
that either RSV may interact with cell-associated LL-37 or that
LL-37 may induce an antiviral state in the epithelial cells.
Interestingly, human b-defensin (hBD)2 has been shown to
destabilise the RSV viral envelope upon contact with soluble
hBD2 in solution, or following exposure to plasma membrane-
associated hBD2 during cell entry [45]. Although LL-37 may
function in a similar manner, the well described capacity of LL-37
to modify cellular responses to inflammatory stimuli raises the
possibility that host defence modulatory capacity is important.
LL-37 has been demonstrated to modulate signalling down-
stream of pattern recognition receptors and differentially induce
and inhibit certain cytokine and chemokines responses, with the
potential to modify the nature of host responses to bacterial and
viral infections [14,46,47]. Interestingly these effects are observed
at peptide concentrations (typically 1–5 mg/ml) that are lower than
those required for microbicidal activity. Although our data
indicate that LL-37-mediated modulation of cellular type –I
interferon responses is not required for the antiviral activity against
RSV observed in this study, the capacity of cathelicidins to
modulate cellular responses to TLR3, 27, 28 and 29 agonists
[22,47,48] may prove to be significant. Indeed, the dramatic
effects of LL-37 on cytokine production and survival in influenza
infected mice, in comparison to the relatively modest effect on
viral loads in vivo [32], also suggests that peptide-mediated
modulation of inflammation and immunity may be an important
component of their antiviral function. In addition to evaluating the
impact of cathelicidins in vivo and the capacity for direct and
indirect antiviral activities of these peptides to act simultaneously,
future studies should also determine the extent to which synergies
exist between cathelicidins and other CHDP (such as defensins)
which have been shown to have activity against RSV.
In conclusion, this study demonstrates a novel antiviral activity
for the sole human cathelicidin LL-37 against RSV, an important
human pathogen for which no effective disease-modifying
therapies exist. It implicates hCAP-18/LL-37 as an important,
targetable component of innate host defence against RSV and
suggests future potential in strategies aimed at prophylactic
modulation of cathelicidin expression in vulnerable individuals
and/or the development of synthetic peptide analogues for use in
post-exposure prophylaxis.
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